News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
Upsher-Smith Laboratories Presents Data Characterizing The Pharmacokinetics And Safety/Tolerability Of Investigational Midazolam Nasal Spray (Usl261) In Pediatric Participants With Epilepsy 10/28/2016
Philogen S.p.A. Receives Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma 10/28/2016
Innate Pharma (IPH.PA ): Encouraging Initial Results For IPH4102 Presented At The Third World Congress Of Cutaneous Lymphomas 10/27/2016
ProQR Therapeutics B.V. (PRQR) Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients 10/27/2016
Bird Rock Bio Submits Clinical Trial Authorization For The First In Human Clinical Trial For Namacizumab 10/27/2016
F2G Announces Publication Of Initial F901318 Data In Scientific Journal PNAS 10/26/2016
National Center for Child Health And Development Initiates Phase 1/2 Trial Of Green Cross' Idursulfase-Beta ICV For The Treatment Of Hunter Syndrome With Neurocognitive Decline 10/26/2016
Apitope Announces Enrolment Of First Patient In Phase I Trial Of ATX-GD-59 For The Treatment Of Graves' Disease 10/26/2016
Entasis Announces Initiation Of Phase I Clinical Trial Of ETX2514 10/26/2016
FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech (ADRO)'s Cancer Vaccine Trial 10/25/2016
Theravance Biopharma (TBPH) Announces Positive Results Including Biomarker Data From Phase 1 Multiple-Ascending Dose Study Of TD-0714, An Inhibitor Of Neprilysin (NEP) 10/25/2016
Why Aduro Biotech (ADRO)'s Clinical Hold Made Investors So Nervous 10/25/2016
AmpliPhi Bio (APHB) Announces Favorable Topline Safety And Tolerability Results From Its Phase I Trial In Patients With Chronic Rhinosinusitis 10/25/2016
SCYNEXIS, Inc. (SCYX) Completes Two Additional Clinical Studies Further Supporting The Favorable Safety Profile Of SCY-078 10/25/2016
Eurocine Vaccines Announces Initiation Of Clinical Study Of The Nasal Influenza Vaccine Candidate Immunose FLU 10/25/2016
Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome 10/24/2016
aTyr Pharma Receives FDA Fast Track Designation For Resolaris To Treat Facioscapulohumeral Muscular Dystrophy (FSHD) 10/24/2016
La Jolla Pharma (LJPC) Receives Positive Opinion From European Orphan Committee For LJPC-401 10/24/2016
Alphamab Starts Clinical Trial On Its First Novel Biologics KN015, A Long-Acting FSH, For In Vitro Fertilization (IVF) 10/24/2016
2 Biotechs Face Key Decisions in Mid-Fourth Quarter 10/21/2016
MorphoSys AG Receives Clinical Milestone For Start Of Phase 1 Trial With Novel Cancer Antibody 10/21/2016
Advaxis (ADXS) Initiates Combination Portion Of Phase I/II Study With Merck & Co. (MRK) 10/20/2016
RadioMedix Successfully Completed The Phase I/ II Clinical Studies For Aminomedix Used For Radiation Kidney Protection During Peptide-Receptor Radionuclide Therapy (PRRT) 10/20/2016
How Pfizer (PFE) is Quietly Rebuilding Its Alzheimer's Pipeline 10/19/2016
PharmaEngine, Inc. Announces Initiation Of Phase 1b/2 Trial Of PEP503 (NBTXR3) In Head And Neck Cancer 10/19/2016
Marinus Pharma (MRNS) Release: Ganaxolone Phase I Data Supports Progressing To Phase II In Patients With Status Epilepticus 10/19/2016
Kite Pharma (KITE) Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day 10/19/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes? 10/18/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
Adaptimmune (ADAP) Announces Initiation Of Triple Tumor Study To Evaluate Its SPEAR T-Cell Therapy Targeting MAGE-A10 10/18/2016
A Look at CRISPR, 'Biotech's Biggest Discovery of the Century,' and the 3 Companies Knee Deep in It 10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat? 10/17/2016
Celgene (CELG) Release: Oral GED-0301 Phase 1b Results Show Clinical Remission And Endoscopic Response At Week 12 In Patients With Active Crohn's Disease 10/17/2016
Rational Vaccines Release: First Ever Human Trial Of A Live Attenuated Functioning Therapeutic Herpes Vaccine 10/17/2016
First Patient Randomized In Multiple Dose Cohort Of Phase 1/1b Trial With TRANSGENE (ENX:TNG)'s TG1050 In Chronic Hepatitis B Patients 10/17/2016
After Setback, Adaptimmune (ADAP) Revamps T Cell Study 10/14/2016
Eisai Inc. (ESALF.PK) Release: Preliminary Results From Lenvatinib + Pembrolizumab Phase 1b Clinical Study In Select Solid Tumors Presented At ESMO 2016 10/14/2016
ESMO 2016 Takeaways: Don't Miss Celldex (CLDX), Exelixis (EXEL) and Tesaro (TSRO) 10/13/2016
Chromocell And Astellas (ALPMY) Announce FDA Fast Track Designation And First Subject Dosing With Lead Candidate CC8464/ASP1807 For The Management Of Neuropathic Pain Associated With iSFN 10/13/2016
True North Therapeutics Receives FDA Orphan Drug Designation For TNT009 For The Treatment Of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD) 10/13/2016
C2N Completes Phase I Clinical Study Of C2N-8E12 (ABBV-8E12) Among Individuals With Progressive Supranuclear Palsy 10/13/2016
Adaptimmune (ADAP) Makes Move to Save Ovarian Cancer Study By Readjusting Its Trial Protocol 10/12/2016
TRANSGENE (ENX:TNG) Announces Collaboration With Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) To Evaluate The Combination Of TG4001 With Avelumab In HPV-Positive Head & Neck Cancer In A Phase I/II Study 10/11/2016
Daiichi Sankyo Presents Late-Breaking Phase 1 Data For Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a In T-DM1 Pre-Treated Breast Cancer At The ESMO 2016 Congress 10/10/2016
CytRx (CYTR) Presents Interim Results From On-Going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress 10/10/2016
OncoMed (OMED) Presents Interim Phase Ib Data For Ipafricept And Vantictumab In Pancreatic Cancer At The ESMO 2016 Congress 10/10/2016
Endocyte (ECYT) Presents Data On Two Lead Clinical Programs At European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016
Corvus Pharma Announces Biomarker Findings From Phase I/IIb Study Of Lead Oral Checkpoint Inhibitor CPI-444 Presented At ESMO 2016 Congress 10/10/2016
TRACON Pharma (TCON) Presents Final Updated Phase Ib Results For TRC105 In Combination With Inlyta In Renal Cell Carcinoma At The ESMO 2016 Congress 10/10/2016
Viralytics Ltd (VLA.AX) Updates CAVATAK and KEYTRUDA Combination Clinical Trials At ESMO 2016 10/10/2016
Novartis AG (NVS) Challenges Pfizer (PFE) Full on With New Breast Cancer Data 10/10/2016
ZIOPHARM Oncology (ZIOP) Falls Some More After Experimental Gene Therapy is Tied to 'Higher Than Expected' Toxicity 10/10/2016
Cascadian Therapeutics (ONTY) Announces Presentation Of Tucatinib In Combination Therapy In Patients With Cutaneous HER2+ Metastatic Breast Cancer 10/10/2016
Ventrix's Shows Early Signs Of Helping Heart Attack Healing 10/10/2016
Global Blood Therapeutics (GBT) Presents GBT440 Data That Continue To Support Durability, Safety And Mechanism Of Action In Sickle Cell Disease 10/7/2016
4 Small Biotechs That Could Give Gilead (GILD), Merck & Co. (MRK) Pfizer (PFE) Some Competition With NASH 10/7/2016
Incyte (INCY) Release: Additional Phase I Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-Naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda (Pembrolizumab) 10/7/2016
Seattle Genetics (SGEN) And Agensys, Inc., An Affiliate Of Astellas (ALPMY), Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress 10/7/2016
Exelixis (EXEL) Announces Phase I Trial Results For Cabozantinib In Combination With Nivolumab In Advanced Genitourinary Tumors 10/7/2016
Q Biomed Comments On Its Glaucoma Drug And Industry News In The Ophthalmology Space 10/7/2016
Kite Pharma (KITE) Presents 12-Month Follow-Up Data From ZUMA-1 Phase I At The European Society For Medical Oncology (ESMO) Annual Congress 10/7/2016
aTyr Pharma Presents Additional Data For Resolaris Phase 1b/2 Trial In Adult Patients With Facioscapulohumeral Muscular Dystrophy At The 21st International Annual Congress Of The World Muscle Society 10/6/2016
Cellectar Biosciences  (CLRB) Announces Enrollment Of First Patient Into Third Cohort Of Its Phase I Clinical Study Of CLR 131 In Multiple Myeloma 10/6/2016
Kite Pharma (KITE) Initiates Phase Ib/II Combination Study For KTE-C19 And Atezolizumab In Patients With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 10/6/2016
A Closer Look at the Pipelines Pfizer (PFE) Inherited From Recent Acquisitions 10/5/2016
Karus Therapeutics Announces First Lymphoma Patients Dosed With KA2237 In Clinical Study At MD Anderson Cancer Center 10/5/2016
Theravance Biopharma (TBPH) Announces First Subject Dosed In Phase 1b Clinical Trial Of TD-1473 In Patients With Moderate To Severe Ulcerative Colitis 10/5/2016
Amgen (AMGN) Release: Study Results Published In Journal Of Clinical Oncology Show BLINCYTO (Blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 10/4/2016
Biologics Candidate Manufactured Using Ajinomoto Althea Inc.'s CORYNEX Protein Expression System Enters Clinical Trials For The First Time 10/4/2016
BTG plc (BTG.L) Release: First Patient In Malaysia Receives TheraSphere Radioembolisation Therapy 10/4/2016
Atrin Pharmaceuticals Awarded $300,000 Phase 1 Contract For Development Of Highly Specific ATR Inhibitors For Targeted Cancer Treatment 10/4/2016
Corvus Pharma To Present Data On Lead Oral Checkpoint Inhibitor CPI-444 At ESMO 2016 Congress 10/4/2016
Massachusetts's Alnylam (ALNY) Falls After Stopping Development of RNAi Liver Disease Candidate ALN-AAT 10/3/2016
AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results 10/3/2016
Videregen's Lead Product Granted EU Orphan Drug Status 10/3/2016
Alkermes (ALKS) Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia 10/3/2016
NW Bio (NWBO) Presents Further DCVax-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference 9/29/2016
Cellectar Biosciences  (CLRB) Announces New Positive Data From Phase I Clinical Study Of CLR 131 In Multiple Myeloma 9/29/2016
Enanta Pharmaceuticals, Inc. Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-Alcoholic Steatohepatitis (NASH) 9/29/2016
Dermata Therapeutics Announces Positive Top-Line Results From Their Phase 1 Pharmacokinetic Study Of DMT210 In Acne Rosacea Patients 9/28/2016
Karyopharm (KPTI) Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication 9/28/2016
Incyte (INCY) Release: Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda (Pembrolizumab) 9/28/2016
Immune Design Corporation (IMDZ) Announces Advancement Of First GLAAS-Based Allergy Program Into Clinical Development 9/28/2016
ARMO BioSciences Announces Data Presentations At The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/27/2016
BeyondSpring Pharmaceuticals Announces First Patient Enrolled In Phase 1b/2 Investigator-Initiated Trial Of Plinabulin Plus Nivolumab For Non-Small Cell Lung Cancer 9/27/2016
Asterias Biotherapeutics Announces Dosing Of First Patient In New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 In An Expanded Cervical Spinal Cord Injury Patient Population 9/27/2016
X4 Pharma Announces Initiation Of Phase Ib Study Of X4P-001 In Patients With Resectable Stage III And Stage IV Melanoma 9/27/2016
Rich Pharma Announces Quarterly Milestones 9/27/2016
Alnylam (ALNY) Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational Rnai Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 9/26/2016
Dicerna (DRNA) Terminates Development of DCR-PH1, Shifts Focus 9/26/2016
Fate Therapeutics (FATE) Receives FDA Orphan Drug Designation For Protmune In Allogeneic Hematopoietic Cell Transplantation 9/26/2016
Idera Pharma (IDRA) Reports Promising Data From Ongoing Phase I Dose Escalation In Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma 9/26/2016
Aerpio Initiates Phase Ia Study Of AKB-4924, A First In Class Once-Daily, Orally Administered HIF-1 Stabilizer, In Development To Treat Inflammatory Bowel Disease (IBD) 9/26/2016
First Patient Dosed In CANBridge Life Sciences’s CAN-008 Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan 9/26/2016
SciClone (SCLN) Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market 9/26/2016
Corvus Pharma Announces Preclinical And Preliminary Clinical Biomarker Data Of Lead Oral Checkpoint Inhibitor CPI-444 Presented At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/26/2016
Faraday Pharma Announces First-In-Human Trial Of FDY-5301 9/23/2016
NW Bio (NWBO) Presents Updated Data From DCVax-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference In London 9/22/2016
First Patient Enrolled In Toca 6, Tocagen's Trial For Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus 9/22/2016
Anaheim Clinical Trials (ACT) Completes Large Phase 1 Trial In Healthy Volunteers And Psoriasis Patients For Major Pharmaceutical Company 9/22/2016
Proteostasis (PTI) Announces Scientific Presentations On New Data At 30th Annual North American Cystic Fibrosis Conference 9/22/2016
Mirna Halts Clinical Study of Lead Drug After Patients Get Sick 9/21/2016
Children’s Of Alabama Seeking Patients For Innovative Phase 1 Trial For Pediatric Brain Tumor Patients 9/21/2016
Zafgen (ZFGN) Initiates Multiple Ascending Dose Cohorts In Phase I Clinical Trial Of ZGN-1061 9/20/2016
VBI Vaccines Completes Enrollment Of Participants In The Phase I Clinical Trial Of Its Preventative Cytomegalovirus Vaccine Candidate 9/20/2016
scPharmaceuticals Announces Presentations On Subcutaneous Furosemide At HFSA Annual Meeting 9/20/2016
AmpliPhi Bio (APHB) Provides Update On Phase I Trial In Chronic Rhinosinusitis Patients 9/20/2016
Bexion Pharmaceuticals Doses First Patient In Phase I Trial Of BXQ-350 For Patients With Advanced Solid Tumors At The University Of Cincinnati Cancer Institute 9/20/2016
Infinity Pharma (INFI) Announces Publication On PI3K-Gamma In Nature 9/19/2016
MabVax Therapeutics Reports On Interim Progress On Its Programs Including The Phase I Clinical Trial For Therapeutic Antibody Treatment Of Pancreatic Cancer 9/19/2016
Fibrocell (FCSC) Completes Enrollment In NC1+ Cohort Of Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 9/19/2016
China Biologic Products Receives CFDA Clinical Trial Approval For Human Coagulation Factor IX 9/19/2016
UK Regulatory Authority Approves Cynata GvHD Clinical Trial 9/19/2016
Parkinson’s Disease: Prexton Therapeutics Completes Phase 1 Clinical Trial 9/19/2016
Seattle Genetics (SGEN) Initiates Phase I Trial Of SGN-CD123A For Patients With Relapsed Or Refractory Acute Myeloid Leukemia 9/19/2016
Corvus PharmaTo Present Data On Lead Oral Checkpoint Inhibitor CPI-444 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/19/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Xencor Initiates Phase 1b Trial Of Subcutaneous Formulation Of Xmab7195 9/15/2016
Zymeworks Doses First Patient In Phase I Trial Of ZW25, A Novel Bi-Specific Antibody For The Treatment Of HER2-Expressing Cancers 9/15/2016
Viamet Release: FDA Grants QIDP Designation To VT-1598 For Treatment Of Valley Fever 9/15/2016
Allakos Begins Clinical Trials Of AK002 In Patients With Systemic Mastocytosis 9/15/2016
Asterias Biotherapeutics AST-OPC1 Treatment For Spinal Cord Injury Patients Shown To Help Patients Paralyzed From The Neck Down Regain Function In The Arms And Hands 9/14/2016
Heat Biologics Resumes Enrollment In Its Non-Small Cell Lung Cancer Trial Evaluating HS-110 In Combination With Anti-PD-1 Checkpoint Inhibitor 9/14/2016
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 1 Clinical Trial Of Drug Candidate GMI-1271 For Multiple Myeloma 9/14/2016
10 Biotechs—Count ‘Em, 10!—With Big Decisions in the Fourth Quarter 9/13/2016
AmpliPhi Bio (APHB) Announces Topline Results From Its Phase I Phage Therapy Trial Conducted In The United States 9/13/2016
Kezar Life Sciences Announces Initiation Of Phase 1 Clinical Program For Lead Candidate KZR-616, A First-In-Class Immunoproteasome Inhibitor 9/13/2016
Aphios To Develop HIV/AIDS Cure Using Combination Drugs In Targeted ‘Nanosomes’ Nanoparticles 9/13/2016
Inotrem Successfully Completes Its First Phase I Clinical Trial With Motrem, A TREM-1 Pathway Modulator For The Treatment Of Septic Shock 9/13/2016
Celgene (CELG) Touts Early Stage Crohn’s Disease Data 9/12/2016
Celgene (CELG) Announces Interim Topline Data From Trial Of Investigational Oral GED-0301 In Patients With Active Crohn’s Disease 9/12/2016
Amplyx Initiates Dosing In Phase 1 Clinical Trial Of APX001, A Novel Antifungal Product Candidate For Treatment Of Life-Threatening Infections 9/12/2016
Xencor Doses First Patient In Lead Immuno-Oncology Bispecific Program Xmab14045 For The Treatment Of Acute Myeloid Leukemia And Other CD123-Expressing Hematologic Malignancies 9/12/2016
Sunesis (SNSS) Presents Dose Escalation Results From The Phase IA Healthy Volunteer Study Evaluating Oral Non-Covalent BTK Inhibitor SNS-062 9/12/2016
MGB Biopharma Limited Granted Qualified Infectious Disease Product (QIPD) Designation By U.S. FDA For The Treatment Of Clostridium Difficile-Associated Diarrhoea (CDAD) For MGB-BP-3 9/12/2016
AmpliPhi Bio (APHB)’ Bacteriophage Cocktail Shown To Prevent C. difficile Biofilm Formation And Reduce Colonization 9/12/2016
Tobira (TBRA) Announces Initiation Of Phase I Combination Study of Cenicriviroc And Evogliptin 9/12/2016
Juno (JUNO) Surges as Small Cancer Study is Hailed a Success, Shows Promise for Other Drugs 9/9/2016
GTx, Inc. (GTXI) Achieves Stage 1 Milestone In Phase II Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer 9/8/2016
La Jolla Pharma (LJPC) Reports Positive Results From Phase 1 Study Of LJPC-401 9/8/2016
Avelas Biosciences Completes Patient Enrollment For AVB-620 Phase 1b Clinical Trial 9/8/2016
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016
La Jolla Pharma (LJPC) Announces Agreement With EMA On Pivotal Study Of LJPC-401 9/8/2016
Boost Vaccination Data Encourage Continued Development of AFFiRiS AG Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein 9/7/2016
Alnylam (ALNY) Reports Positive Interim Results From Ongoing Phase I Study Of ALN-AS1, An Investigational Rnai Therapeutic For The Treatment Of Acute Hepatic Porphyrias 9/7/2016
Sensorion Announces Positive Results From SENS-218 Phase I Clinical Trial Undertaken In The UK 9/7/2016
Capricor Therapeutics, Inc. Completes Enrollment In Randomized HOPE Clinical Trial In Duchenne Muscular Dystrophy 9/7/2016
Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting The Potential Clinical And Health Economic Impact Of EG-1962 In Aneurysmal Subarachnoid Hemorrhage 9/7/2016
Proclara Announces Initiation Of Phase Ib Clinical Trial Of NPT088 For Alzheimer’s Disease 9/7/2016
Arrowhead Pharma (ARWR) Doses First Patient With Hepatitis B In Multiple Ascending Dose Portion Of Phase I/II Study Of ARC-521 9/7/2016
BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications 9/7/2016
Sangamo (SGMO) Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing 9/6/2016
GlycoMimetics, Inc. (GLYC) Initiates Dosing In Phase I Clinical Trial Of GMI-1359 9/6/2016
Peloton Therapeutics Announces Dual Publications Of HIF-2a Antagonism In Kidney Cancer In The Journal Nature 9/6/2016
Biogen (BIIB)’s Shares Rise After FDA Fast Tracks Alzheimer’s Drug 9/2/2016
Oncotelic And Autotelic Announce Clinical Data Supporting IL-8 Spike As A Prognostic Biomarker For Immunotherapy 9/2/2016
Edge Therapeutics To Present Additional Data From Phase I/II NEWTON Study Of EG-1962 At Two Scientific Conferences In September 9/2/2016
Biogen (BIIB)'s Experimental Alzheimer’s Drug Shows Promise in Human Trials 9/1/2016
Viking Therapeutics (VKTX) Presents Phase 1 Data And Highlights Ongoing Phase 2 Study Of VK5211 At 5th Fragility Fracture Network Global Congress 2016 9/1/2016
GenSight Biologics Receives Orphan Drug Designation And Advanced Therapy Medicinal Product Classification In Europe For GS030 In Retinitis Pigmentosa 9/1/2016
Fibralign Announces Enrollment Initiated For Stanford University-Led Clinical Trial For Breast Cancer-Related Lymphedema 9/1/2016
Neurimmune Therapeutics Release: Early Results Show Aducanumab Removes Amyloid Plaques In Patients With Alzheimer’s Disease 8/31/2016
InCarda Initiates Enrollment Of Phase 1 Clinical Trial Of Inhaled Flecainide For The Treatment Of Cardiac Arrhythmias 8/31/2016
Asterias Biotherapeutics Receives Safety Clearance To Begin Administering The Highest Dose Of AST-OPC1 In The SCiStar Phase 1/2a Clinical Trial In Cervical Spinal Cord Injury Patients 8/31/2016
Oncternal Therapeutics Initiates Patient Dosing In Phase 1 Clinical Trial Of TK216 In Ewing Sarcoma 8/30/2016
Syros Pharma’s Scientific Founders Publish On First Selective CDK12 And CDK13 Inhibitor As Promising Approach For Treatment Of Cancer 8/30/2016
Abeona Therapeutics Completes Enrollment Of Low-Dose Cohort For ABO-102 In Phase 1/2 Clinical Trial For MPS IIIA Patients 8/29/2016
Gradalis Inc. Announces Dosing Of First Patient In Pilot Study Combining Vigil Engineered Autologous Tumor Cell Immunotherapy And Durvalumab In Advanced Breast Cancer 8/29/2016
BirchBioMed Announces Completion Of Clinical Trial For Ground-Breaking Anti-Scarring Drug 8/26/2016
Pivotal Study Results Published In The New England Journal of Medicine Confirm Safety And Efficacy Of InSightec's Exablate Neuro System For The Treatment Of Essential Tremor 8/25/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
Prima Biomed (PRR.AX): Operational Update 8/19/2016
ScarX Therapeutics Announces Approval For Trial Of First Clinically-Promising Scar Reduction Cream 8/18/2016
Zymeworks’ ZW25 And ZW33 Granted Orphan Drug Designation for Ovarian Cancer By U.S. FDA 8/18/2016
Karos Pharmaceuticals Announces Major Milestone Events 8/18/2016
New First-in-Pediatrics Trial At Children's Hospital Los Angeles To Test AstraZeneca Pharmaceuticals LP (AZN)'s Durvalumab For Certain Cancers 8/18/2016
Audentes (BOLD) Announces First Patient Enrolled In The INCEPTUS Clinical Assessment Study Of XLMTM 8/17/2016
Evofem Announces First Patient Enrolled In A Clinical Trial To Determine The Effect And Duration Of Amphora Gel On Vaginal Ph 8/17/2016
Regen BioPharma Receives New Preliminary HemaXellerate Clinical Data On Bone Marrow Suppression From Pan Am Cancer Treatment Center 8/16/2016
ARMO BioSciences Announces Publication Of AM0010 Clinical Data In Advanced Solid Tumor Patients In Journal Of Clinical Oncology (JCO) 8/16/2016
FDA: Toxicity Seen In Fatal French Study Does Not Extend To Other FAAH Inhibitors 8/15/2016
Results From Phase 1 Trials With Ligand (LGND)’s LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism 8/15/2016
AbGenomics Corporation Announces FDA Acceptance To Commence Phase I Clinical Trial Of Abgn-107 ADC Candidate For Pancreatic, Gastric, And Colorectal Cancer Treatments 8/15/2016
Sun BioPharma Announces Completion Of The Second Patient Cohort And Starts Recruitment Of Third Cohort Patients In The Dose Escalation Phase 1 Study Of SBP101 For Pancreatic Cancer 8/15/2016
Tivorsan Pharmaceuticals, Inc. Granted FDA Orphan Drug Designation For Human Recombinant Biglycan In The Treatment Of Duchenne Muscular Dystrophy 8/15/2016
Fractyl’s Revita DMR Significantly Improves Hyperglycemia In Type 2 Diabetes Patients 8/12/2016
KalVista Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of KVD818 For The Treatment Of Hereditary Angioedema 8/11/2016
SAb Biotherapeutics Release: Phase I Clinical Trials Underway For First MERS Treatment 8/11/2016
Biocryst (BCRX) Announces Initiation Of The Apex-1 Clinical Trial Of BCX7353 For Hereditary Angioedema 8/11/2016
Inovio Pharma (INO) Expands Positive Phase I Ebola Vaccine Trial To Identify Most Optimal Immunization Regimen 8/11/2016
Vigilant Biosciences Awarded Phase I SBIR Grant For Next Generation Oral Cancer Diagnostic System 8/11/2016
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease 8/10/2016
RetroSense Therapeutics Completes Low Dose Cohort In Clinical Trial Of Novel Gene Therapy Application Of Optogenetics 8/10/2016
TARIS Biomedical Launches Second Phase 1b Clinical Trial Of TAR-200 (Gemris) In Patients With Bladder Cancer 8/10/2016
Amphivena Therapeutics Announces Acceptance Of Investigational New Drug (IND) Application For AMV564 And Planned Phase 1 Trial Initiation 8/10/2016
Novartis AG (NVS)'s New Asthma Drug Hailed a Game-Changer After Success in Small Trial 8/9/2016
Can-Fite BioPharma (CFBI)'s Phase II/III Psoriasis Study Results Published In Journal Of Drugs In Dermatology 8/8/2016
San Diego’s Pfenex (PFNX) Regains Full Rights to PF582 and Announces Phase I/II Results 8/8/2016
Pfenex (PFNX) Announces Positive Anthrax Vaccine Study Results 8/8/2016